Lexington-Fayette, Kentucky 2020-11-19 18:14:06 –
Indianapolis — A new drug from Eli Lilly and Company to assist inpatient COVID-19 patients in need of oxygen has received an emergency license from the US Food and Drug Administration.
Balibitinib, used in combination with remdesivir, has been identified for COVID-19 cases and requires oxygen supplementation, invasive ventilator, or extracorporeal membrane oxygenation for adults aged 2 years and older and It can be administered to both pediatric patients. Oxygenation.
“Since the launch of the COVID-19 pandemic, Lily has been working to find potential treatments to help people around the world affected by the virus,” said Lily’s Chairman and CEO. One David A. Rix said in a press release. .. “Today’s FDA measures for baricitinib show a second lily therapy given with EUA, in addition to the recent neutralizing antibody EUA for high-risk, unhospitalized patients, at various stages in COVID-19 patients. Increase the number of treatment options in. This is an important milestone in oxygen therapy for inpatients, as baricitinib can help accelerate recovery. “
According to a press release, patients treated with drugs in combination with remdesivir “had a significant reduction in median time to recovery.”
According to a press release, baricitinib has not been approved by the FDA for the treatment of COVID-19 and clinical trials are still underway.
Eli Lilly and Company works with the healthcare system and government to give patients access to the drug.
“In terms of supply, Lily is confident that it can meet the needs of patients under the EUA in the United States and existing approved indications around the world,” the press release read.
Click here for more information on the drug.
Earlier this month, Eli Lilly and Company received an emergency license for experimental COVID-19 antibody treatment.
This article was written by Andrew Smith for WRTV.